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ABSTRACT
Background: The role of gluconeogenesis from protein in the
pathogenesis of weight loss in lung cancer is unclear.
Objective: Our aim was to study gluconeogenesis from alanine
in lung cancer patients and to analyze its relation to the degree
of weight loss.
Design: In this cross-sectional study, we used primed-constant
infusions of [6,6-2H2]-D-glucose and [3-13C]-L-alanine to assess
whole-body glucose and alanine turnover and gluconeogenesis
from alanine in weight-losing (WL, n = 9) and weight-stable (WS,
n = 10) lung cancer patients and healthy control (n = 15) subjects.
Results: Energy intake and plasma alanine concentrations did
not differ significantly among the subject groups. Mean ( – SEM)
whole-body glucose production was significantly higher in WL
than in WS and control subjects (0.74 – 0.06 compared with
0.55 – 0.04 and 0.51 – 0.04 mmol · kg21 · h21, respectively,
P < 0.01). Alanine turnover was significantly elevated in WL
compared with WS and control subjects (0.57 – 0.04 compared
with 0.42 – 0.05 and 0.40 – 0.03 mmol · kg21 · h21, respectively,
P < 0.01). Gluconeogenesis from alanine was significantly
higher in WL than in WS and control subjects (0.47 – 0.04
compared with 0.31 – 0.04 and 0.29 – 0.04 mmol · kg21 · h21,
respectively, P < 0.01). The degree of weight loss was positively
correlated with glucose and alanine turnover and with gluconeo-
genesis from alanine (r = 0.45 for all, P < 0.01).
Conclusions: Aberrant glucose and alanine metabolism occurred
in WL lung cancer patients. These changes were related to the
degree of weight loss and not to the presence of lung cancer per se.
Am J Clin Nutr 2000;71:583–9.
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INTRODUCTION
Weight loss is frequently observed in patients with cancer.
Evidence shows that weight loss in such patients is associated
with poor treatment outcome and reduced survival (1–3). Weight
loss may occur in the early stages of cancer, even before there
are other signs that a tumor is present. Although animal studies
suggest that the development of weight loss in cancer is closely
related to both the presence and the size of the tumor (4), in
humans the relations between weight loss and the size, extent,
stage, and type of tumor are less clear (5).
When cancer patients lose weight, they lose both fat and muscle
mass (6). In comparison with anorectic patients who have the same
degree of weight loss, cancer patients lose relatively more muscle
mass (7). Although anorexia is a frequent phenomenon in cancer
patients, reduced food intake by itself does not explain these
patients’ loss of lean body mass. This suggests that derangements
in host metabolism must be a major contributing factor (1, 8).
Metabolic alterations in cancer patients include elevated glu-
cose turnover and increased endogenous glucose production,
according to previous studies (5, 9–12). Other studies reported net
protein catabolism, mainly from muscle, in cancer patients who
were losing weight, whereas in cancer patients with stable weights
no change in protein catabolism was observed (13). It has been
hypothesized that in cancer patients, increased amounts of alanine
originating from muscle degradation are used for gluconeogenesis
(4, 14), with consequent loss of nitrogen through urea production.
However, studies of gluconeogenesis from alanine in tumor-bear-
ing animals (15) and cancer patients (16, 17) have been inconclu-
sive with regard to the relation to weight loss. Furthermore, the
studies conducted previously did not account for anorexia as a
potential confounder; food intake data were usually not collected.
The incidence of weight loss in lung cancer patients is high,
yet anorexia and obstruction are less likely to be the cause of the
observed weight loss with this tumor type than with other can-
cers. Elevated protein turnover rates have been reported in lung
cancer patients experiencing weight loss, but the role of gluco-
neogenesis from protein in the pathogenesis of weight loss in
this type of cancer has remained unclear (18).
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The aim of the present study was to evaluate protein-derived
gluconeogenesis in a well-defined group of lung cancer patients.
Alanine was selected as a precursor of gluconeogenesis because
it is the key protein-derived glucose precursor used by the liver
(19). Patients who were and who were not losing weight were
included to differentiate between possible effects of lung cancer
and of the degree of weight loss on gluconeogenesis.
SUBJECTS AND METHODS
Subjects
Patients with histologically proven non-small-cell lung cancer
who received care at the outpatient department of the University
Hospital Rotterdam in the Netherlands were recruited. Two
groups of lung cancer patients were studied: those who had lost
‡ 5% of their body weight in the previous 6 mo (weight-losing,
WL) and those who had not lost weight in the previous 6 mo
(weight-stable, WS). Patients were only included after an inter-
val of ‡ 3 mo after surgery or ‡ 4 wk after chemotherapy or radio-
therapy. Patients who were in remission or were apparently
cured were excluded. Other exclusion criteria were pregnancy,
metabolic disease, corticosteroid treatment, liver metastases con-
firmed by computed tomography or ultrasound, alcohol con-
sumption of > 10 units/wk, and use of a slimming diet. Healthy,
weight-stable control subjects were included as a reference
group. The study was approved by the Medical Ethical Commit-
tee of the Erasmus University Medical Center Rotterdam. All
participants signed informed consent forms.
Dietary intake
Food intake was recorded by using a standard food diary dur-
ing the 7 d preceding the experiment. The subjects received oral
and written information from a trained nutritionist (SL) about the
procedures for filling in the diary and measuring all drinks and
foods with household measures. Subjects were asked to maintain
their usual dietary habits, and none of the subjects reported any
significant changes in their diets. Subjects abstained from alco-
hol for 5 d before the experiment. All medications taken by the
subjects were noted.
Household measures were converted into weights by using a
standard food conversion table (Department of Human Nutrition,
Wageningen, Netherlands) and the nutrition software program
KOMEET (version 2.0; B-Ware, Arnhem, Netherlands). The
subjects’ average daily intakes of energy, fat, carbohydrate, and
protein were calculated.
Study design
We measured the subjects’ body weight, height, upper arm cir-
cumference, and 4 skinfold thicknesses (triceps, biceps, sub-
scapular, and suprailiac). Skinfold thicknesses were measured
with a standard skinfold caliper (Holtain Ltd, London). Body
mass index in kg/m2 was calculated, and upper arm muscle cir-
cumference was calculated as described by Frisancho (20).
Subjects were studied in the morning after an overnight fast. A
cannula (0.8 3 25 mm) was positioned in the left cubital vein for
the infusion of stable isotope tracers. In the contralateral cubital
vein, an identical cannula was positioned for blood sampling. To
study gluconeogenesis, we prepared a solution containing [6,6-
2H2]-D-glucose, 98 atom%, and [3-13C]-L-alanine, 99 atom% (Mass
Trace, Woburn, MA), in water; the solution was sterilized by
autoclaving in glass vials. A priming dose of 0.03 mmol [6,6-
2H2]-D-glucose/kg was administered followed by a continuous
infusion of 0.01 mmol [6,6-2H2]-D-glucose · kg21 · h21 for 90
min. Simultaneously, a priming dose of 0.08 mmol [3-13C]-L-ala-
nine/kg was given followed by a continuous infusion of
0.04 mmol [3-13C]-L-alanine ·kg21 · h21 over 90 min. Both tracer
solutions were infused by using calibrated syringe pumps (Per-
fusor fm; Braun, Kronberg, Germany).
Venous blood samples were drawn immediately before the
isotope infusions were started and then at 10-min intervals from
60 to 90 min, when steady state conditions for the tracer infu-
sions had been achieved. Plasma concentrations of glucose, ala-
nine, insulin, glucagon, and thyroid hormones and isotopic
enrichments of glucose and alanine were determined.
Analytic methods
Blood samples were collected in tubes containing lithium
heparin (Vacutainer; Becton Dickinson, Meylan Cedex, France)
and were immediately stored on ice. After centrifugation (1200 3
g for 10 min at 4 8C) of the samples, the plasma was collected
and stored at 220 8C until analyzed. An aliquot of the infusate
was analyzed to document the actual concentrations of the trac-
ers in each study.
Blood glucose concentrations were determined enzymatically
with a glucose oxidase and peroxidase assay system (Boehringer
Mannheim, Mannheim, Germany). Plasma alanine concentra-
tions were measured enzymatically as described by Williamson
(21). Plasma concentrations of insulin and glucagon were deter-
mined by radioimmunoassay techniques (Biosource, Fleurus,
Belgium and Euro-Diagnostica, Malmo, Sweden, respectively).
Serum total thyroxine (T4) and triiodothyronine (T3) concentra-
tions were measured by radioimmunoassay and total reverse tri-
iodothyronine (rT3) concentrations were measured according to
the method of Bauer et al (22).
Isotopic enrichments were determined by using the following
procedures. Plasma was deproteinized by adding 0.3 mol barium
hydroxide/L (Sigma Diagnostics, St Louis) and 0.3 mol zinc sul-
fate/L (Merck, Darmstadt, Germany). After centrifugation
(15 000 3 g for 8 min at 4 8C), the supernate was applied to an
ion-exchange column (mixed bed: AG50W-X8 and AG1-X8,
200–400 mesh, 0.2 g each; BioRad, Hercules, CA). Glucose and
alanine were eluted from the column by using water and 4 mol
ammonium hydroxide/L (Merck), respectively, and were dried
under nitrogen.
A glucose derivative (aldonitril pentaacetate) was made
according to the method of Varma et al (23). An alanine tert-
butyldimethylsilyl derivative was prepared as described by
Chaves Das Neves and Vasconcelos (24).
Isotopic enrichments were measured by injecting 1-mL sam-
ples with a split ratio of 50:1 on a fused silica capillary column
(25 m 3 0.22 mm) coated with 0.11-mm high-temperature 5%
phenylpolycarborane siloxane (SGE, Victoria, Australia). The
relative isotopic enrichments of deuterated glucose and [13C]ala-
nine were determined by using a Carlo Erba GC8000 gas chro-
matograph coupled to a Fisons MD800 mass spectrometer
(Interscience BV, Breda, Netherlands) in electron impact ioniza-
tion mode. The CV for enrichment was 0.2 mol% for both
[6,6–2H2]glucose and [3-13C]alanine and no concentration effect
was observed at this level of enrichment. Ions were selectively
monitored at a mass-to-charge ratio (m/z) of 187 for natural
glucose and m/z 189 for the deuterated molecule. The isotopic
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enrichment of [3-13C]alanine was determined at m/z 260 and 261
for [12C]alanine and [13C]alanine, respectively (25).
The total enrichment of [13C]glucose was measured separately
(aldonitril pentaacetate derivation) by using a gas chromatograph
combustion isotope ratio mass spectrometer (Optima; Micro-
mass UK, Middlewich, Cheshire, United Kingdom). The [13C]glu-
cose enrichment in atom percent excess (APE) was monitored
after combustion to carbon dioxide at mass 44 for carbon-12 and
mass 45 for carbon-13.
Calculations and statistics
Whole-body rate of appearance (Ra) for glucose and alanine
was calculated during steady state based on a one-compartment
model by using the following formula:
Ra = F 3 [(IEi/IEecf) 2 1] (1)
where F is the isotope infusion rate in mmol · kg21 · h21, IEi is the
isotopic enrichment of the infusate in mol percent excess (MPE),
and IEecf is the isotopic enrichment of the extracellular fluid
(plasma) in MPE (26).
The percentage glucose produced from alanine equals
IE [13C]glucoseplasma/(IE [13C]alanineplasma 3 0.33) (2)
where IE [13C]glucoseplasma is the isotopic enrichment in plasma
(expressed as 13CO2 APE). Because alanine has 3 carbon atoms,
100% enrichment of [3-13C]alanine in MPE is equivalent to 33%
enrichment of 13CO2 from alanine (APE). Therefore, the enrich-
ment of alanine (MPE) is multiplied by 0.33 to obtain compara-
ble enrichments (ie, expressed as 13CO2 APE) for both alanine
and glucose. Gluconeogenesis from alanine in mmol · kg21 · h21
was then obtained as follows:
Percentage glucose from alanine 3 Ra ([2H2]glucose) (3)
Finally, the percentage of alanine converted into glucose was cal-
culated by dividing the rate of gluconeogenesis from alanine by
the rate of appearance of alanine (27).
The results are presented as means – SEMs. Differences
among group means were compared by using analysis of vari-
ance with dummies for lung cancer and weight loss as covariates,
with adjustment for age. Bonferroni correction was applied to
allow for multiple testing. Correlations between variables were
determined by using Pearson’s product-moment correlation
coefficients. Multiple linear regression analysis was used to ana-
lyze interrelationships, with adjustment for possible con-
founders. Differences were considered statistically significant at
P < 0.05. Data were analyzed with SPSS for WINDOWS (ver-
sion 8; SPSS Inc, Chicago).
RESULTS
Study population
The subjects were 19 lung cancer patients and 15 healthy con-
trol subjects (3 men and 12 women). Of the lung cancer patients,
9 (7 men and 2 women) were classified as WL and 10 (6 men and
4 women) were classified as WS. The cancer patients had been
diagnosed with non-small-cell lung cancer at the following stages
(World Health Organization grading system): IIIA (1 WS, 3 WL),
IIIB (3 WS, 2 WL), and IV (6 WS, 4 WL). The characteristics of
the study population are presented in Table 1. The cancer patients
were significantly older than the control subjects. The WL patients
had lost 9.0 – 1.4 kg or 12% (range: 6–22%) of their pre-illness
stable body weight within the 6 mo preceding the study. Body
weight, percentage of ideal body weight, body mass index, midup-
per arm circumference, and the sum of 4 skinfold thicknesses were
all significantly lower in the WL patients than in the WS patients
and the control subjects. Upper arm muscle circumference was
slightly, but not significantly, lower in the WL patients than in the
WS patients and control subjects. Albumin and transthyretin (pre-
albumin) concentrations were lower in the WL patients than in the
WS patients and control subjects (P < 0.01).
Dietary intake
None of the subjects reported any changes in their food intake
compared with their pre-illness food intake. Carbohydrate intake
preceding the experiment was ‡ 200 g/d in all subjects (Table 2).
No significant differences in energy, carbohydrate, protein, or fat
intakes were found among the groups.
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TABLE 1
Characteristics of the study population1
Lung cancer patients
Control subjects WS WL
(n = 15) (n = 10) (n = 9)
Age (y) 52 (29–72)a,b,2 63 (38–75)a 69 (53–81)b
Height (m) 1.74 – 0.02 1.69 – 0.03 1.71 – 0.03
Weight (kg) 77.2 – 2.5a 73.5 – 3.8b 60.9 – 3.5a,b
Percentage ideal body weight (%) 123.0 – 4.1a 119.3 – 6.4b 96.0 – 5.0a,b
Weight loss in past 6 mo (%) — 22.0 – 1.0a 12 – 2a
Body mass index (kg/m2) 25.7 – 0.8a 25.6 – 1.3b 20.9 – 1.1a,b
Arm circumference (cm) 32.1 – 1.0a 30.3 – 1.4b 26.1 – 1.2a,b
Arm muscle circumference (cm) 26.1 – 0.9 26.0 – 0.9 24.4 – 1.4
Sum of skinfold thicknesses (mm)3 69.6 – 4.0a 64.6 – 8.4b 29.8 – 3.8a,b
Albumin (g/L) 46 – 1a 44 – 1b,4 38 – 2a,b,4
Transthyretin (g/L) 0.29 – 0.01a 0.28 – 0.02b,4 0.17 – 0.02a,b
1 x– – SEM. Differences among group means were determined by using analysis of variance; means within a row with a superscript letter in common are
significantly different, P < 0.05. WS, weight stable; WL, weight losing.
2 Range in parentheses.
3 Calculated as the sum of the biceps, triceps, subscapular, and suprailiac skinfold thicknesses.
4 One value was missing.
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Glucose and alanine metabolism
Baseline plasma glucose and alanine concentrations did not
differ significantly between the lung cancer patients and healthy
control subjects, but glucose concentrations were significantly
higher in WL patients than in WS patients (Table 3). Steady state
was reached within 60 min after the isotope tracer infusions
began, as judged from visual inspection of isotope enrichment
profiles. Relative isotopic enrichments of [2H2]glucose, [13C]ala-
nine, and [13C]glucose in plasma during steady state did not dif-
fer significantly among the groups.
Turnover rates of glucose and alanine are shown in Figure 1.
The whole-body glucose turnover rate was significantly higher
in WL lung cancer patients than in WS lung cancer patients or
healthy control subjects. Similarly, the alanine turnover rate was
significantly higher in WL patients than in the other 2 groups.
Gluconeogenesis from alanine was significantly elevated in WL
patients when compared with both WS patients and control sub-
jects. The percentage of glucose derived from alanine was
64.6 – 4.2% in WL patients, 60.2 – 11.8% in WS patients, and
55.0 – 4.8% in control subjects (NS) and the percentage of ala-
nine converted into glucose was 84.2 – 6.9%, 70.4 – 7.1%, and
70.0 – 7.1% in these 3 groups, respectively (NS). Glucose and
alanine turnover rates and gluconeogenesis from alanine were
positively correlated with the degree of weight loss (r = 0.45,
P < 0.01 for all) and inversely correlated with percentage of ideal
body weight (r = 20.38, 20.44, and 20.50, respectively, P < 0.05
for all). The relation between gluconeogenesis from alanine and
weight change in lung cancer patients is shown in Figure 2.
No correlations were found between turnover measurements
and subject sex or age. Multivariate analyses showed that only
the degree of weight loss was a significant predictor of glucose
and alanine turnover and of gluconeogenesis from alanine. No
associations were found between energy, carbohydrate, and pro-
tein intakes on the day before the experiment and plasma glucose
or alanine concentrations or turnover measurements.
Hormone concentrations
Fasting insulin and glucagon concentrations and the insulin-
to-glucagon ratio were not significantly different between lung
cancer patients and healthy control subjects (Table 4). However,
glucagon concentrations in WL patients were lower than those in
WS patients (P < 0.01). The insulin-to-glucagon ratio was signi-
ficantly correlated with alanine turnover (r = 20.36, P = 0.04).
No other significant correlations between insulin or glucagon
concentrations and turnover measurements were observed. T4
and T3 concentrations did not differ significantly among the
groups. In contrast, the rT3 concentration and rT3-to-T3 ratio
were significantly elevated in WL lung cancer patients and were
correlated with the degree of weight loss (r = 0.47 and 0.53,
respectively, P < 0.01 for both). Reverse T3 concentrations were
also correlated with glucose turnover (r = 0.36, P = 0.03).
DISCUSSION
The present study was designed to quantify gluconeogenesis
from alanine in both WL and WS patients with advanced lung
cancer, as compared with healthy control subjects. Although sev-
eral authors reported abnormal glucose metabolism in patients
with advanced malignant disease (7, 9, 10, 12, 28), few studies
have been done with lung cancer patients. Heber et al (11)
reported elevated glucose turnover rates in 65% of patients who
had non-small-cell lung cancer with weight loss.
Furthermore, elevated rates of whole-body protein turnover
have been measured in cancer patients by using different amino
acids (8, 10, 13, 28, 29), but data from lung cancer patients are
sparse and inconclusive regarding the role of weight loss. Richards
et al (30), who used a primed-constant infusion of [15N]glycine,
reported increased protein turnover rates in patients who had
advanced lung cancer with weight loss. Melville et al (18) also
found elevated protein turnover by using [13C]leucine in patients
with newly diagnosed nonmetastatic lung cancer, but these authors
did not observe any relation with weight loss. Fearon et al (31)
studied lung cancer patients (stages II or III) who were and who
were not losing weight; whole-body protein turnover rates as
measured by [15N]glycine were elevated in all cancer patients but
again, no relation with weight loss was observed. Heber et al (32)
used [14C]lysine to measure protein turnover rate in lung cancer
patients and found that it was elevated and inversely correlated
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TABLE 2
Daily intake of energy and selected nutrients in healthy control subjects
and weight-stable (WS) and weight-losing (WL) lung cancer patients1
Lung cancer patients
Control subjects WS WL
(n = 15) (n = 10) (n = 9)
Energy (kJ/d) 7838 – 401 8260 – 405 8170 – 644
Fat
(g/d) 77 – 5 80 – 5 74 – 9
(% of energy) 37 – 1 37 – 1 34 – 2
Carbohydrate
(g/d) 206 – 13 224 – 12 231 – 16
(% of energy) 45 – 2 46 – 1 48 – 1
Protein
(g/d) 79 – 4 85 – 5 81 – 5
(% of energy) 17 – 1 18 – 1 17 – 1
1 x– – SEM. Data were obtained from 7-d food records. Differences
among group means were determined by using anlysis of variance, adjusted
for age; no significant differences were found.
TABLE 3
Plasma glucose and alanine concentrations and isotopic enrichments of
plasma glucose and alanine during turnover measurements in healthy
control subjects and weight-stable (WS) and weight-losing (WL) lung
cancer patients1
Lung cancer patients
Control subjects WS WL
(n = 15) (n = 10) (n = 9)
Glucose (mmol/L) 5.9 – 0.2 5.2 – 0.2a 5.8 – 0.3a
Alanine (mmol/L) 347 – 6 368 – 8 349 – 13
Isotopic enrichment of plasma
[2H2]Glucose (MPE) 2.19 – 0.25 1.88 – 0.19 1.55 – 0.13
[13C]Alanine (MPE) 8.78 – 0.78 8.32 – 0.62 7.22 – 0.60
[13C]Glucose (APE) 1.52 – 0.14 1.49 – 0.18 1.53 – 0.13
1 x– – SEM. Isotopic enrichments were determined under steady state
conditions during primed-constant infusions of [6,6-2H2]-D-glucose and
[3-13C]-L-alanine. Differences among group means were determined by
using analysis of variance, adjusted for age; means within a row with a
superscript letter in common are significantly different, P < 0.05. MPE,
mole percent excess; APE, 13CO2 atom percent excess.
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with percentage of ideal body weight but not with degree of
weight loss. In the present study, alanine turnover was signifi-
cantly correlated with both degree of weight loss and percentage
of ideal body weight in lung cancer patients.
To date, gluconeogenesis from alanine in cancer patients has
been studied only by using a single bolus infusion of [14C]ala-
nine (ie, not in steady state conditions). Waterhouse et al (16)
reported elevated rates of alanine-to-glucose conversion in WL
cancer patients with mixed tumor types and metastatic disease
when compared with undernourished subjects without cancer.
Dietary intake was not reported in that study. Burt et al (17)
reported elevated rates of alanine turnover that were not related
to the degree of weight loss in patients with localized esophageal
cancer. The present study, which was performed under steady
state conditions with infusion of [2H2]glucose and [13C]alanine,
showed that gluconeogenesis from alanine was elevated in WL
but not in WS lung cancer patients.
Note that the approach of using [13C]alanine underestimates
gluconeogenesis because 13C is diluted in intracellular pyruvate
pools and at oxaloacetate, caused by exchange with the tricar-
boxylic acid cycle (26). We assumed that the yield of transfer of
13C from alanine to glucose via the oxaloacetate crossover in the
liver and the extent of 13CO2 reincorporation via gluconeogenesis
into carbons 3 and 4 of glucose were identical in all 3 groups.
Furthermore, as a result of rapid exchange of 13C between alanine
and pyruvate/lactate, gluconeogenesis may include a contribution
from Cori cycling. We were able to measure 13C enrichment of
lactate and found no significant differences among healthy con-
trol subjects, WS patients, and WL patients. Food intake was
carefully monitored in all subjects by means of dietary records
kept for the 7 d preceding the turnover measurements. The results
revealed no significant differences in energy intake among the
groups; in fact, lung cancer patients tended to have higher energy
intakes than did healthy control subjects. This indicates that
weight loss and turnover measurements in our study population
of lung cancer patients were not related to reduced food intake.
Several mechanisms may be responsible for the elevated gluco-
neogenesis from alanine in WL lung cancer patients. Increased
gluconeogenesis could be caused by decreased insulin or increased
glucagon concentrations (33, 34). However, in our study and stud-
ies by others (7, 11, 32), fasting insulin concentrations were not
decreased in WS or WL lung cancer patients. Furthermore, no
significant difference in glucagon concentrations between lung
cancer patients and healthy control subjects was observed. Rofe
et al (34) reported an altered insulin response and insulin-to-
glucagon ratio in cancer patients with various tumor types,
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FIGURE 1. Mean ( – SEM) whole-body rate of appearance (turnover) of glucose and alanine and gluconeogenesis from alanine in healthy control
subjects (n = 15) and weight-stable (WS, n = 10) and weight-losing (WL, n = 9) lung cancer patients. Turnover rates were assessed by using primed-
constant infusions of [6,6-2H2]glucose and [3-13C]alanine. **Significantly different from WS lung cancer patients and healthy control subjects, P < 0.01
(ANOVA, adjusted for age).
FIGURE 2. Gluconeogenesis from alanine in lung cancer patients
plotted against the percentage change from pre-illness stable body
weight during the previous 6 mo (n = 19; r is Pearson’s product-moment
correlation coefficient). Gluconeogenesis from alanine was assessed by
using primed-constant infusions of [6,6-2H2]glucose and [3-13C]alanine. 
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although there was no consistent relation with the degree of
weight loss in these patients. Clearly, it is not possible to define
mechanisms on the basis of plasma concentrations of insulin or
glucagon alone; however, our data do not support a predominant
role for insulin or glucagon concentrations in causing the observed
alterations in gluconeogenesis in WL lung cancer patients.
A second hypothesis is that elevated gluconeogenesis from ala-
nine is the result of increased substrate availability or increased
transport of alanine into the liver. In animal studies in vivo, ala-
nine concentrations in the livers of tumor-bearing hosts were ele-
vated (35) but plasma concentrations were normal (36) or
decreased (33), which suggests increased uptake of alanine by the
liver. Reduced plasma alanine concentrations in WL lung cancer
patients were reported by some authors (11, 37). However, in the
present study we did not detect differences in plasma alanine
concentrations among WL and WS lung cancer patients and
healthy control subjects despite a 36% increase in alanine flux in
the WL cancer patients. Moreover, no correlation between
plasma alanine concentrations and alanine turnover rates was
observed (r = 20.08, P = 0.67). Based on our results, it would
therefore seem unlikely that the elevated alanine turnover rate
would result simply from increased plasma alanine concentra-
tions. However, the possibility of increased alanine uptake by the
liver cannot be ruled out on the basis of our data.
Other possible mechanisms are the acute-phase response and
circulating cytokines (38–40) or elevated activity of one or more
gluconeogenic enzymes within the liver, as has been shown in
vitro for phosphoenolpyruvate carboxykinase, glucose-6-phos-
phatase (41), and pyruvate carboxylase (42). In WL lung cancer
patients, hydrazine sulfate reduced glucose production (43) and
increased plasma alanine concentrations (44), probably by
inhibiting phosphoenolpyruvate carboxykinase. However, no
data on hepatic gluconeogenic enzyme activities in humans with
lung cancer are available.
Gluconeogenesis is an energy-consuming process, and enhanced
conversion of alanine into glucose could therefore act as an energy-
depleting mechanism. Although elevated gluconeogenesis may be
an important factor in the pathology of weight loss in lung cancer,
this does not preclude contributions from other energy-wasting
processes to weight loss in lung cancer patients. Nevertheless,
increased gluconeogenesis from alanine could result in loss of
body protein. It is thought that loss of muscle mass contributes to
impaired muscle function and decreased survival (2, 45).
In summary, elevated rates of glucose and alanine turnover and
gluconeogenesis from alanine were detected in patients who had
advanced lung cancer with weight loss. These metabolic abnor-
malities were not related to either the presence of lung cancer or
reduced energy intake. Prospective studies on the relation between
elevated gluconeogenesis from alanine and weight loss in lung
cancer, and the underlying mechanisms, are warranted. 
We thank HJ Agteresch, CCM Bartels, M Heijsteeg, F Lagerwaard, MJM
van Mierlo, S Senan, R Slingerland, G Stoter, MMA Tilanus-Linthorst, and AG
Zwanenburg for their cooperation during patient recruitment. We are grateful
to P Kappert, W Schneijderberg, and C Onna (Daniel den Hoed Cancer Cen-
ter, Rotterdam, Netherlands) for their assistance during the experiments.
REFERENCES
1. Costa G, Lane WW, Vincent RG, Siebold JA, Aragon M, Bewley PT.
Weight loss and cachexia in lung cancer. Nutr Cancer 1980;2:98–103.
2. Dewys WD, Begg C, Lavin PT, et al. Prognostic effect of weight
loss prior to chemotherapy in cancer patients. Eastern Cooperative
Oncology Group. Am J Med 1980;69:491–7.
3. Stanley KE. Prognostic factors for survival in patients with inoper-
able lung cancer. J Natl Cancer Inst 1980;65:25–32.
4. Argiles JM, Azcon-Bieto J. The metabolic environment of cancer.
Mol Cell Biochem 1988;81:3–17.
5. Kern KA, Norton JA. Cancer cachexia. JPEN J Parenter Enteral
Nutr 1988;12:286–98.
6. Heymsfield SB, McManus CB. Tissue components of weight loss in
cancer patients. A new method of study and preliminary observa-
tions. Cancer 1985;55:238–49.
7. Douglas RG, Shaw JH. Metabolic effects of cancer. Br J Surg
1990;77:246–54.
8. Emery PW, Edwards RH, Rennie MJ, Souhami RL, Halliday D. Pro-
tein synthesis in muscle measured in vivo in cachectic patients with
cancer. Br Med J 1984;289:584–6.
9. Holroyde CP, Gabuzda TG, Putnam RC, Paul P, Reichard GA.
Altered glucose metabolism in metastatic carcinoma. Cancer Res
1975;35:3710–4.
10. Lundholm K, Edstrom S, Karlberg I, Ekman L, Schersten T. Glu-
cose turnover, gluconeogenesis from glycerol, and estimation of net
glucose cycling in cancer patients. Cancer 1982;50:1142–50.
11. Heber D, Byerly LO, Chlebowski RT. Metabolic abnormalities in
the cancer patient. Cancer 1985;55:225–9.
12. Tayek JA, Katz J. Glucose production, recycling, Cori cycle, and
gluconeogenesis in humans: relationship to serum cortisol. Am J
Physiol 1997;272:E476–84.
13. Shaw JH, Humberstone DA, Douglas RG, Koea J. Leucine kinetics
in patients with benign disease, non-weight-losing cancer, and can-
cer cachexia: studies at the whole-body and tissue level and the
response to nutritional support. Surgery 1991;109:37–50.
14. Burt ME, Lowry SF, Gorschboth C, Brennan MF. Metabolic alterations
in a noncachectic animal tumor system. Cancer 1981;47:2138–46.
15. Arbeit JM, Burt ME, Rubinstein LV, Gorschboth CM, Brennan MF.
Glucose metabolism and the percentage of glucose derived from
alanine: response to exogenous glucose infusion in tumor-bearing
and non-tumor-bearing rats. Cancer Res 1982;42:4936–42.
16. Waterhouse C, Jeanpretre N, Keilson J. Gluconeogenesis from ala-
nine in patients with progressive malignant disease. Cancer Res
1979;39:1968–72.
17. Burt ME, Gorschboth CM, Brennan MF. A controlled, prospective,
randomized trial evaluating the metabolic effects of enteral and par-
enteral nutrition in the cancer patient. Cancer 1982;49:1092–105.
18. Melville S, McNurlan MA, Calder AG, Garlick PJ. Increased pro-
tein turnover despite normal energy metabolism and responses to
feeding in patients with lung cancer. Cancer Res 1990;50:1125–31.
588 LEIJ-HALFWERK ET AL
TABLE 4
Fasting hormone concentrations in healthy control subjects and weight-
stable (WS) and weight-losing (WL) lung cancer patients1
Lung cancer patients
Control subjects WS WL
(n = 15) (n = 10) (n = 9)
Insulin (pmol/L) 64.2 – 8.5 77.3 – 19.9 57.4 – 15.4
Glucagon (pmol/L) 5.7 – 0.7 8.1 – 0.9 6.5 – 1.6
Insulin:glucagon 12.4 – 1.6 9.4 – 1.4 18.4 – 7.3
T4 (nmol/L) 100 – 10 107 – 5 103 – 8
T3 (nmol/L) 1.85 – 0.12 1.87 – 0.06 1.63 – 0.17
rT3 (nmol/L) 0.26 – 0.02a 0.30 – 0.03b 0.40 – 0.05a,b
rT3:T3 0.15 – 0.02a 0.16 – 0.02 0.27 – 0.05a
1 x– – SEM. Differences among group means were determined by using
analysis of variance, adjusted for age; means within a row with a super-
script letter in common are significantly different, P < 0.05. T4, thyroxine;
T3, triiodothyronine; rT3, reverse triiodothyronine.
2 One value was missing.
 at Swets Subscription Service 76130274 on Decem
ber 4, 2006 
w
w
w
.ajcn.org
D
ow
nloaded from
 
19. Stumvoll M, Meyer C, Perriello G, Kreider M, Welle S, Gerich J.
Human kidney and liver gluconeogenesis: evidence for organ sub-
strate selectivity. Am J Physiol 1998;274:E817–26.
20. Frisancho AR. Triceps skin fold and upper arm muscle size norms
for assessment of nutrition status. Am J Clin Nutr 1974;27:1052–8.
21. Williamson DH. L-Alanin; Bestimmung mit Alanin-Dehydrogenase. (L-
Alanine; analyses using alanine dehydrogenase.) In: Bergmeyer HU, ed.
Methoden der Enzymatischen Analyse. (Methods of enzymatic analy-
ses.) Weinheim, Germany: Verlag Chemie, 1970:1634–7 (in German).
22. Bauer AG, Wilson JH, Lamberts SW, Docter R, Hennemann G, Visser
TJ. Handling of iodothyronines by the liver and kidney in patients
with chronic liver disease. Acta Endocrinol 1987;116:339–46.
23. Varma R, Varma RS, Allen WS, Wardi AH. Gas chromatographic
determination of neutral sugars from glycoproteins and acid
mucopolysaccharides as aldononitrile acetates. J Chromatogr
1973;86:205–10.
24. Chaves Das Neves HJ, Vasconcelos AM. Capillary gas chromatog-
raphy of amino acids, including asparagine and glutamine: sensitive
gas chromatographic-mass spectrometric and selected ion monitor-
ing gas chromatographic-mass spectrometric detection of the
N,O(S). J Chromatogr 1987;392:249–58.
25. Martineau A, Lecavalier L, Falardeau P, Chiasson JL. Simultaneous
determination of glucose turnover, alanine turnover, and gluconeo-
genesis in humans using a double stable-isotope-labeled tracer infu-
sion and gas chromatography-mass spectrometry analysis. Anal
Biochem 1985;151:495–503.
26. Wolfe RR. Radioactive and stable isotope tracers in medicine: prin-
ciples and practice of kinetic analysis. New York: Wiley-Liss, 1992.
27. Consoli A, Nurjhan N, Reilly J Jr, Bier DM, Gerich JE. Contribu-
tion of liver and skeletal muscle to alanine and lactate metabolism
in humans. Am J Physiol 1990;259:E677–84.
28. Koea JB, Shaw JH. The effect of tumor bulk on the metabolic
response to cancer. Ann Surg 1992;215:282–8.
29. Dworzak F, Ferrari P, Gavazzi C, Maiorana C, Bozzetti F. Effects of
cachexia due to cancer on whole body and skeletal muscle protein
turnover. Cancer 1998;82:42–8.
30. Richards EW, Long CL, Nelson KM, et al. Protein turnover in
advanced lung cancer patients. Metabolism 1993;42:291–6.
31. Fearon KC, Hansell DT, Preston T, et al. Influence of whole body
protein turnover rate on resting energy expenditure in patients with
cancer. Cancer Res 1988;48:2590–5.
32. Heber D, Chlebowski RT, Ishibashi DE, Herrold JN, Block JB.
Abnormalities in glucose and protein metabolism in noncachectic
lung cancer patients. Cancer Res 1982;42:4815–9.
33. Inculet RI, Peacock JL, Gorschboth CM, Norton JA. Gluconeogen-
esis in the tumor-influenced rat hepatocyte: importance of tumor
burden, lactate, insulin, and glucagon. J Natl Cancer Inst 1987;79:
1039–46.
34. Rofe AM, Bourgeois CS, Coyle P, Taylor A, Abdi EA. Altered
insulin response to glucose in weight-losing cancer patients. Anti-
cancer Res 1994;14:647–50.
35. Rivera S, Azcon-Bieto J, Lopez-Soriano FJ, Miralpeix M, Argiles
JM. Amino acid metabolism in tumour-bearing mice. Biochem J
1988;249:443–9.
36. Arbeit JM, Gorschboth CM, Brennan MF. Basal amino acid con-
centrations and the response to incremental glucose infusion in
tumor bearing rats. Cancer Res 1985;45:6296–300.
37. Cascino A, Muscaritoli M, Cangiano C, et al. Plasma amino acid
imbalance in patients with lung and breast cancer. Anticancer Res
1995;15:507–10.
38. Scott HR, McMillan DC, Crilly A, McArdle CS, Milroy R. The rela-
tionship between weight loss and interleukin 6 in non-small-cell
lung cancer. Br J Cancer 1996;73:1560–2.
39. Mantovani G, Maccio A, Esu S, et al. Medroxyprogesterone acetate
reduces the production of cytokines and serotonin involved in
anorexia/cachexia and emesis by peripheral blood mononuclear cells
of cancer patients. Eur J Cancer 1997;33:602–7.
40. Tisdale MJ. Wasting in cancer. J Nutr 1999;129:243S–6S.
41. Gutman A, Thilo E, Biran S. Enzymes of gluconeogenesis in tumor-
bearing rats. Isr J Med Sci 1969;5:998–1001.
42. Liu KJ, Kleps R, Henderson T, Nyhus L. 13C NMR study of hepatic
pyruvate carboxylase activity in tumor rats. Biochem Biophys Res
Commun 1991;179:366–71.
43. Chlebowski RT, Heber D, Richardson B, Block JB. Influence of
hydrazine sulfate on abnormal carbohydrate metabolism in cancer
patients with weight loss. Cancer Res 1984;44:857–61.
44. Tayek JA, Heber D, Chlebowski RT. Effect of hydrazine sulphate on
whole-body protein breakdown measured by 14C-lysine metabolism
in lung cancer patients. Lancet 1987;2:241–4.
45. Nixon DW, Heymsfield SB, Cohen AE, et al. Protein-calorie under-
nutrition in hospitalized cancer patients. Am J Med 1980;68:
683–90.
WEIGHT LOSS AND GLUCONEOGENESIS IN LUNG CANCER 589
 at Swets Subscription Service 76130274 on Decem
ber 4, 2006 
w
w
w
.ajcn.org
D
ow
nloaded from
 
